ISD-Immunotech

📍 Copenhagen, Denmark🗓 Founded 2013👥 1 employees💰 Last funded Nov 2020
Biotechnology Research🌐 isd-immunotech.com
Website LinkedIn
ISD Immunotech is developing STING modulators to treat severe Systemic lupus erythematosus (SLE) or Lupus by targeting the STING pathway. SLE is a complex and devastating autoimmune disease with few to no good options for treatment especially for the most severe patients. STimulator of INterferon Gene (STING) is a target that controls innate immunity and has shown to be overactive in severe SLE making it an exciting new therapeutic target for SLE.
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Denmark
2
Frequently asked questions
Who invested in ISD-Immunotech?
ISD-Immunotech has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did ISD-Immunotech last raise funding?
The most recent investment in ISD-Immunotech recorded on gritt.io was in November 2020.
When was ISD-Immunotech founded?
ISD-Immunotech was founded in 2013.
What industry is ISD-Immunotech in?
ISD-Immunotech operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is ISD-Immunotech based?
ISD-Immunotech is headquartered in Copenhagen, Denmark.